about
Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosetsCannabinoid CB(1) receptors in the basal ganglia and motor response to activation or blockade of these receptors in parkin-null miceTranscription factors NRF2 and NF-κB are coordinated effectors of the Rho family, GTP-binding protein RAC1 during inflammation.Endocannabinoids and basal ganglia functionality.The endogenous cannabinoid system and the basal ganglia. biochemical, pharmacological, and therapeutic aspects.An overview of Parkinson's disease and the cannabinoid system and possible benefits of cannabinoid-based treatments.Spinocerebellar ataxia 2 (SCA2).Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease.Role of microglial redox balance in modulation of neuroinflammation.Nuclear import and export signals control the subcellular localization of Nurr1 protein in response to oxidative stress.Activation of apoptosis signal-regulating kinase 1 is a key factor in paraquat-induced cell death: modulation by the Nrf2/Trx axis.Design, synthesis and biological evaluation of novel arachidonic acid derivatives as highly potent and selective endocannabinoid transporter inhibitors.Hypolocomotor effects in rats of capsaicin and two long chain capsaicin homologues.Fractalkine activates NRF2/NFE2L2 and heme oxygenase 1 to restrain tauopathy-induced microgliosis.Nrf2 deficiency potentiates methamphetamine-induced dopaminergic axonal damage and gliosis in the striatum.Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.Involvement of vanilloid-like receptors in the effects of anandamide on motor behavior and nigrostriatal dopaminergic activity: in vivo and in vitro evidence.Potential involvement of cannabinoid receptors in 3-nitropropionic acid toxicity in vivo.Nrf2 protects the lung against inflammation induced by titanium dioxide nanoparticles: A positive regulator role of Nrf2 on cytokine release.Pituitary adenylate cyclase-activating polypeptide stimulates glial fibrillary acidic protein gene expression in cortical precursor cells by activating Ras and Rap1.Insulin receptor and lipid metabolism pathology in ataxin-2 knock-out mice.Pharmacological targeting of GSK-3 and NRF2 provides neuroprotection in a preclinical model of tauopathy.Cx3cr1-deficiency exacerbates alpha-synuclein-A53T induced neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.Loss of cannabinoid CB(1) receptors in the basal ganglia in the late akinetic phase of rats with experimental Huntington's diseaseRole of MSK1 in the Induction of NF-κB by the Chemokine CX3CL1 in Microglial CellsCannabinoid CB2 Receptor Modulation by the Transcription Factor NRF2 is Specific in Microglial CellsNRF2 and Primary Cilia: An Emerging Partnership
P50
Q28203208-D0FD25E3-A8D4-47B9-9FED-846FB4DE3457Q28585963-2917AA61-B4B6-489A-8961-8D461253D150Q34075866-69170606-0C48-45E7-88FF-88265CE8B477Q34673154-43690C37-FAE1-4DAA-B472-E711A55AE654Q34786832-B50CB36B-475C-4C17-AE2E-5D76ACB80C6BQ36683513-C9881833-FA35-4A96-8E93-9D356B45A498Q37140787-5F40FAD7-8160-4768-A20A-0FAEEAADE7EEQ37253331-E76BAF4B-72F1-4966-AE06-95B6BDE847BFQ37440658-6C2EC561-05E6-46FA-A870-431D91571AD5Q39217465-91ACC27F-8EAB-4DDF-8BAC-EB5ACF0C7C7FQ39732353-8D16F8AD-FD9F-4EB2-BE43-8E143A2EA63EQ40764005-650F074D-D709-4471-8701-ED8DB996F387Q40799260-D7F57DE5-A523-4A02-AE2D-A1CFE17D7B1BQ42252979-9E37AFE8-21B1-499F-A0F8-3B25235F12CEQ42493676-65C32F7C-F1B6-4ADE-8F28-13FD64673757Q42517324-6A30BC39-03EE-4EE3-BDC4-EC71395494C2Q42624110-284D5062-13CE-4693-B98F-D49489B5DB64Q45217300-9749A7E2-A9E2-40F1-993C-98966696F16FQ46119294-4AFC0CD8-A0DF-43A1-BB24-A186E2AAD993Q46426757-9A6AEA4B-6D48-4AC9-BA03-33AD66013102Q46771800-ECDADF07-0A4C-40FE-9796-438D1641A89EQ47113551-57EB0C44-DBC0-4D20-A1AE-52F28A5CA242Q54240535-18B0BC63-5691-45D8-8BB3-72B1627825C5Q73304376-65B53C0D-C339-4162-9119-3BA72992727BQ92106431-8B7CCCC6-C602-4E64-8F5E-54D6BBF5F251Q92439991-44B6E75E-55D9-4F6B-BF04-07EF998EED0DQ96128090-43D9D48B-F218-49AA-8469-758DDA110823
P50
description
researcher
@en
wetenschapper
@nl
name
Isabel Lastres-Becker
@en
Isabel Lastres-Becker
@nl
type
label
Isabel Lastres-Becker
@en
Isabel Lastres-Becker
@nl
prefLabel
Isabel Lastres-Becker
@en
Isabel Lastres-Becker
@nl
P106
P31
P496
0000-0002-4968-2175